LIGHTHOUSE Trial for XLRS Gene Therapy Initiates Dosing of Second Cohort
Atsena Therapeutics has announced that dosing has begun for the second cohort in LIGHTHOUSE, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201, a gene therapy intended to treat X-linked retinoschisis.